<a href="#" class="link-open" aria-expanded="true" onclick="hideCatalogData('28', '3', '95639', '', this, ''); return false;">
				BIOT 2300 - Regulatory Affairs Process for Biopharmaceuticals			</a>
						<br>
			<table class="td_dark">
				<tr>
					<td class="coursepadding">
							<div class="ajaxcourseindentfix social-media-ajax">
                                <div class='acalog-social-media-links'> </div>					<span class="print_link">[<a href="javascript:acalogPopup('preview_course.php?catoid=28&coid=95639&print', 'preview_course', 770, 530, 'yes')" class="acalog-highlight-ignore" alt="Text Version" title="Print Course (opens a new window)">Print Course (opens a new window)</a>]</span>
				</div>
<div><h3>BIOT 2300 - Regulatory Affairs Process for Biopharmaceuticals </h3>  <p><hr>The course will explore the regulations and requirement of new product filing process by which the FDA has used successfully to safe guard the public interest from novel therapeutic drug products.  Some of the key steps by which life science and pharmaceutical companies used to assemble their product development data on discovery, preclinical studies, CMC process, and clinical studies for FDA filing will be examined.  This course will show the students the important process of regulatory filing for new drug development so that students may appreciate the extensive product development hurdles, documentation, validation, and quality control of every step to assure a successful filing.  Although the course will focus on the known regulatory platforms in small molecule and biologic filings, some discussion on the new fields of cell and gene therapies will be compared and contrasted with the established filing platforms.<br><br><strong>Prerequisites:</strong> BIOT 1000 Introduction of Biotechnology</p>

<p>BIOT 1200 Business Operations Management for Biotechnology</p>

<p>COMM 2100 Scientific and Technical Communications<br><br><strong>Anticipated Terms Offered:</strong> fall,<br><br></p></div>		</td>
	</tr>
</table>
<br>
